Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Bullboard Posts
Comment by canadapieton Jul 22, 2019 3:08pm
79 Views
Post# 29947886

RE:RE:RE:interest in TH

RE:RE:RE:interest in THjfm1330 - (7/22/2019 3:02:54 PM) 
RE:RE:interest in TH
There is no Trogarzo disapointment in my view, just misleading informations from Taimed and Taiwan analysts and uninformed analysis on our part here. If I would have known 13 months ago that 10% of peak sales was at best what we could expect from the first year on the market, I would have sold the whole thing back then at 14$, only to buy back later at half the price or less. But I was not properly informed on the reality, on the real numbers to expect from the first year on the market of a biologic drug that is IV, first in class and aiming at a niche market and very expensive. The disapointment is not in the sales numbers of Trogarzo, it is in the fact that I was not good enough to get the good information 13 months ago. We all missed the boat here. That's the reality.



And how many are on the product now???? 

Thx
Bullboard Posts